Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

被引：0
|
作者：
Keller, Anne-Valerie [1 ]
Hajiyianni, Marina [2 ]
Kurre, Eileen [1 ]
Mai, Elias Karl [1 ,2 ]
Bertsch, Uta [1 ,2 ,3 ]
Benner, Axel [4 ]
Luntz, Steffen [5 ]
Raab, Marc-Steffen [1 ,2 ]
Besemer, Britta [6 ]
Michel, Christian Sebastian [7 ]
Schroers, Roland [8 ]
Fenk, Roland [9 ]
Salwender, Hans [10 ]
Blau, Igor Wolfgang [11 ]
Haenel, Mathias [2 ,12 ]
Mann, Christoph [13 ]
Goldschmidt, Hartmut [1 ,2 ,3 ]
机构：
[1] Heidelberg Univ Hosp, Internal Med Hematol Oncol & Rheumatol 5, GMMG Study Grp, Heidelberg, Germany
[2] Univ Hosp Heidelberg, Heidelberg Myeloma Ctr, Dept Med 5, Heidelberg, Germany
[3] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany
[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[5] Coordinat Ctr Clin Trials KKS, Heidelberg, Germany
[6] Univ Hosp Tubingen, Dept Internal Med 2, Tubingen, Germany
[7] Univ Hosp Mainz, Dept Internal Med 3, Mainz, Germany
[8] Univ Hosp Bochum, Med Clin, Bochum, Germany
[9] Univ Hosp Dusseldorf, Dept Haematol Oncol & Clin Immunol, Dusseldorf, Germany
[10] Asklepios Hosp Hamburg Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
[11] Med Klin M S Hamatol Onkol & Tumorimmunol, Berlin, Germany
[12] Klinikum Chemnitz, Dept Internal Med 3, Chemnitz, Germany
[13] Philipps Univ Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-194188
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5140 / 5142
页数：3
相关论文
共 50 条
  • [41] Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies
    Cavo, Michele
    Goldschmidt, Hartmut
    Rosinol, Laura
    Pantani, Lucia
    Zweegman, Sonja
    Salwender, Hans Jurgen
    Jose Lahuerta, Juan
    Lokhorst, Henk M.
    Petrucci, Maria Teresa
    Blau, Igor
    Oriol, Albert
    Testoni, Nicoletta
    Weisel, Katja
    Rios, Rafael
    Patriarca, Francesca
    Blanchard, Jesus
    Dozza, Luca
    Mateos, Maria-Victoria
    Galli, Monica
    San-Miguel, Jesus F.
    Boccadoro, Mario
    Blade, Joan
    Sonneveld, Pieter
    BLOOD, 2018, 132
  • [42] FIRST ANALYSIS OF HOVON-65/GMMG-HD4 RANDOMIZED PHASE III TRIAL COMPARING BORTEZOMIB, ADRIAMYCINE, DEXAMETHASONE (PAD) VS VAD AS INDUCTION TREATMENT PRIOR TO HIGH DOSE MELPHALAN (HDM) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Sonneveld, P.
    van der Holt, B.
    Schmidt-Wolf, I. G. H.
    Bertsch, U.
    El Jarari, L.
    Salwender, H.
    Zweegman, S.
    Vallenga, E.
    Schubert, J.
    Blau, I. W.
    Jie, G. S. K.
    Beverloo, B.
    Jauch, A.
    Hose, D.
    Schaafsma, R.
    Kersten, M. J.
    Delforge, M.
    Raymakers, R. A.
    De Weerdt, O.
    Van der Griend, R.
    Weijermans, P. W.
    Martin, H.
    Van der Velde, H.
    Lokhorst, H. M.
    Goldschmidt, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 191 - 191
  • [43] First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonneveld, P.
    van der Holt, B.
    Schmidt-Wolf, I. G. H.
    Bertsch, U.
    el Jarari, L.
    Salwender, Hans-Juergen
    Zweegman, S.
    Vellenga, E.
    Schubert, J.
    Blau, I. W.
    Jie, G. S. K.
    Beverloo, B.
    Jauch, A.
    Hose, D.
    Schaafsma, R.
    Kersten, M. J.
    Delforge, M.
    de Weerdt, O.
    van der Griend, R.
    Wijermans, R. W.
    Martin, Hans
    van der Velde, H.
    Lokhorst, Henk M.
    Goldschmidt, H.
    BLOOD, 2008, 112 (11) : 243 - 244
  • [44] The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
    Cook, Gordon
    Royle, Kara-Louise
    O'Connor, Sheila
    Cairns, David A.
    Ashcroft, A. John
    Williams, Cathy D.
    Hockaday, Anna
    Cavenagh, Jamie D.
    Snowden, John A.
    Ademokun, Debo
    Tholouli, Eleni
    Andrews, Vivienne E.
    Jenner, Matthew
    Parrish, Christopher
    Yong, Kwee
    Cavet, Jim
    Hunter, Hannah
    Bird, Jenny M.
    Pratt, Guy
    Drayson, Mark T.
    Brown, Julia M.
    Morris, Treen C. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 450 - 467
  • [45] Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma
    Garfall, Alfred L.
    Nooka, Ajay K.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Nooka, Ajay
    van de donk, Niels
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas
    Rosinol, Laura
    Mateos Manteca, Maria-Victoria
    Bahlis, Nizar J.
    Garfall, Alfred
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S80 - S80
  • [47] Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
    Schweighofer, Carmen D.
    Ritgen, Matthias
    Eichhorst, Barbara F.
    Busch, Raymonde
    Abenhardt, Wolfgang
    Kneba, Michael
    Hallek, Michael
    Wendtner, Clemens-Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) : 95 - 98
  • [48] Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database
    Kaedbey, Rayan
    Reece, Donna
    Venner, Christopher P.
    Mccurdy, Arleigh
    Su, Jiandong
    Chu, Michael
    Louzada, Martha
    Jimenez-Zepeda, Victor H.
    Mian, Hira
    Song, Kevin
    Sebag, Michael
    Stakiw, Julie
    White, Darrell
    Reiman, Anthony
    Aslam, Muhammad
    Kotb, Rami
    Bergstrom, Debra
    Gul, Engin
    Leblanc, Richard
    EJHAEM, 2024, 5 (03): : 474 - 484
  • [49] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    Mekan, Sabeen
    Sy, Oumar
    Weisel, Katja
    Richardson, Paul G.
    CANCER, 2018, 124 (20) : 4032 - 4043
  • [50] Long term follow-up shows no clinical benefit for CD34+ selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma:: An EBMT phase III randomized study.
    Bourhis, JH
    Bouko, Y
    Koscielny, S
    Greinix, H
    Derigs, G
    Salles, G
    Feremans, W
    Bakkus, M
    Apperley, J
    Samson, D
    Bjorkstrand, B
    Niederwieser, D
    Gahrton, G
    Pico, JL
    Goldschmidt, H
    BLOOD, 2004, 104 (11) : 264A - 264A
12345